Table 1.
Doses of evidence based therapies over time by treatment allocation
| ESC target total daily dose (mg) | Baseline | 6‐month follow‐up | 12‐month follow‐up | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Enalapril | Sac/Val | P‐value | Enalapril | Sac/Val | P‐value | Enalapril | Sac/Val | P‐value | ||
| β‐blocker | ||||||||||
| Carvedilol | 50 | 22 ± 18 (n = 1658) | 22 ± 18 (n = 1630) | 0.39 | 22 ± 18 (n = 1565) | 22 ± 18 (n = 1554) | 0.84 | 23 ± 19 (n = 1468) | 23 ± 18 (n = 1473) | 0.69 |
| Metoprolol succinate | 200 | 74 ± 54 (n = 892) | 79 ± 60 (n = 922) | 0.06 | 76 ± 54 (n = 862) | 78 ± 59 (n = 873) | 0.58 | 77 ± 57 (n = 816) | 78 ± 59 (n = 832) | 0.60 |
| Bisoprolol | 10 | 6 ± 6 (n = 1111) | 5 ± 3 (n = 1114) | 0.39 | 6 ± 7 (n = 1070) | 5 ± 3 (1087) | 0.40 | 6 ± 7 (n = 1006) | 5 ± 3 (n = 1047) | 0.31 |
| MRA | ||||||||||
| Spironolactone | – | 29 ± 17 (n = 2206) | 30 ± 17 (n = 2101) | 0.42 | 29 ± 16 (n = 2075) | 30 ± 17 (n = 1991) | 0.41 | 29 ± 16 (n = 1935) | 30 ± 17 (n = 1911) | 0.79 |
| Eplerenone | – | 28 ± 12 (n = 173) | 28 ± 10 (n = 158) | 0.98 | 29 ± 13 (n = 167) | 29 ± 10 (n = 175) | 0.97 | 29 ± 14 (n = 176) | 28 ± 11 (n = 173) | 0.39 |
Based on as‐treated cohort.
ESC, European Society of Cardiology; MRA, mineralocorticoid receptor antagonist; Sac/Val, sacubitril/valsartan.